AU716245B2 - A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium - Google Patents

A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium Download PDF

Info

Publication number
AU716245B2
AU716245B2 AU29197/97A AU2919797A AU716245B2 AU 716245 B2 AU716245 B2 AU 716245B2 AU 29197/97 A AU29197/97 A AU 29197/97A AU 2919797 A AU2919797 A AU 2919797A AU 716245 B2 AU716245 B2 AU 716245B2
Authority
AU
Australia
Prior art keywords
inhibitor
metal
factor viii
cell culture
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29197/97A
Other languages
English (en)
Other versions
AU2919797A (en
Inventor
Lars Adamson
Johan Dixelius
Kristina Lima Lie
Erik Walum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9601855A external-priority patent/SE9601855D0/xx
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Publication of AU2919797A publication Critical patent/AU2919797A/en
Application granted granted Critical
Publication of AU716245B2 publication Critical patent/AU716245B2/en
Assigned to PHARMACIA AB reassignment PHARMACIA AB Request to Amend Deed and Register Assignors: PHARMACIA & UPJOHN AB
Assigned to BIOVITRUM AB reassignment BIOVITRUM AB Alteration of Name(s) in Register under S187 Assignors: PHARMACIA AB
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AU29197/97A 1996-05-14 1997-05-13 A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium Ceased AU716245B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9601855 1996-05-14
SE9601855A SE9601855D0 (sv) 1996-05-14 1996-05-14 Process for producing a protein
US1887496P 1996-05-29 1996-05-29
US60/018874 1996-05-29
PCT/SE1997/000783 WO1997043436A1 (en) 1996-05-14 1997-05-13 A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium

Publications (2)

Publication Number Publication Date
AU2919797A AU2919797A (en) 1997-12-05
AU716245B2 true AU716245B2 (en) 2000-02-24

Family

ID=26662616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29197/97A Ceased AU716245B2 (en) 1996-05-14 1997-05-13 A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium

Country Status (13)

Country Link
US (1) US5851800A (https=)
EP (1) EP0934424B1 (https=)
JP (2) JP2000509994A (https=)
AT (2) ATE321141T1 (https=)
AU (1) AU716245B2 (https=)
CA (1) CA2253287C (https=)
DE (2) DE69735510T2 (https=)
DK (1) DK0934424T3 (https=)
ES (2) ES2270460T3 (https=)
NO (2) NO325358B1 (https=)
NZ (1) NZ332751A (https=)
PT (2) PT1318198E (https=)
WO (1) WO1997043436A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
ATE330003T1 (de) * 1999-08-05 2006-07-15 Baxter Ag Rekombinanter stabiler zellklon, seine herstellung und verwendung
WO2001052891A1 (fr) * 2000-01-20 2001-07-26 Nippon Organon K. K. Inhibiteurs d'invasion plasmodiale dans des erythrocytes
PT2287288E (pt) * 2002-07-09 2012-12-10 Baxter Int Meio isento de proteína animal para cultura de células
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
DE60335024D1 (de) * 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
US20040265964A1 (en) * 2003-04-25 2004-12-30 Martin Allen Inducers of recombinant protein expression
US7255288B2 (en) * 2004-03-08 2007-08-14 Wan Shan Chan Aroma therapy for fountain
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
LT2126106T (lt) 2007-02-23 2018-01-10 Sk Chemicals Co., Ltd. Viii faktoriaus ir jo darinių gavimo ir gryninimo būdas
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2008135498A2 (en) * 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN107190034A (zh) 2010-10-05 2017-09-22 诺沃—诺迪斯克保健股份有限公司 生产蛋白质的方法
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
AU2017358289C1 (en) 2016-11-10 2025-05-08 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4203189A (en) * 1988-08-16 1990-03-23 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
AU1492692A (en) * 1987-12-08 1992-10-29 Zymogenetics Inc. Co-expression in eukaryotic cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US5279939A (en) * 1986-08-18 1994-01-18 Smithkline Beecham Corporation Protein protease inhibitors from streptomyces
US4891356A (en) * 1987-07-15 1990-01-02 Brigham & Women's Hospital Proteinase inhibitors for treatment of gastrointestinal ulcer disease
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
WO1990002175A1 (en) * 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE69133064T2 (de) * 1990-02-26 2003-03-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Identifizierung und expression von insekten-steroidrezeptor-dns-sequenzen
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
US5661034A (en) * 1991-07-18 1997-08-26 Fuji Yakuhin Kogyo Kabushiki Kaisha Serum-free medium for tissue culture containing tissue inhibitor of metalloproteinases and method for growing cells using the medium
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
WO1995005477A1 (en) * 1993-08-12 1995-02-23 University Of Maryland Thermostable alkaline metalloprotease produced by a hyphomonas, and preparation thereof
US5631159A (en) * 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1492692A (en) * 1987-12-08 1992-10-29 Zymogenetics Inc. Co-expression in eukaryotic cells
AU4203189A (en) * 1988-08-16 1990-03-23 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YEAST, (1993), 9(4), 379-387 *

Also Published As

Publication number Publication date
CA2253287A1 (en) 1997-11-20
WO1997043436A1 (en) 1997-11-20
JP4896999B2 (ja) 2012-03-14
EP0934424B1 (en) 2006-07-26
DE69736391T2 (de) 2007-08-16
DE69735510T2 (de) 2006-08-24
CA2253287C (en) 2008-02-19
JP2000509994A (ja) 2000-08-08
NO20065027L (no) 1999-01-14
EP0934424A1 (en) 1999-08-11
PT934424E (pt) 2006-12-29
US5851800A (en) 1998-12-22
DE69735510D1 (de) 2006-05-11
DK0934424T3 (da) 2006-11-20
ATE321141T1 (de) 2006-04-15
NO985297L (no) 1999-01-14
NO325633B1 (no) 2008-06-30
ATE334223T1 (de) 2006-08-15
AU2919797A (en) 1997-12-05
DE69736391D1 (de) 2006-09-07
NO985297D0 (no) 1998-11-13
ES2260524T3 (es) 2006-11-01
PT1318198E (pt) 2006-08-31
NO325358B1 (no) 2008-04-07
JP2009148271A (ja) 2009-07-09
ES2270460T3 (es) 2007-04-01
NZ332751A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
AU716245B2 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
KR100616028B1 (ko) 인자 ⅷ을 위한 발현 시스템
KR101798813B1 (ko) 세포 배양 방법
Fenton et al. Thrombin active-site regions
KR101756354B1 (ko) Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
EP0784633B1 (en) Process for purifying factor viii
JPH0387173A (ja) ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
SG186935A1 (en) Method of producing recombinant adamts13 in cell culture
IL124123A (en) Preparation of recombinant factor VIII, recombinant factor VIII produced according to the method and substrate for cell culture for use in the method
US5641647A (en) Serum free medium
EP1318198B1 (en) Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
US6933136B2 (en) Method for making recombinant proteins
Sharma Key issues in the purification and characterization of recombinant proteins for therapeutic use
AU2017261523B2 (en) Cell culture medium for adamts protein expression
Muranova et al. Anti-adhesive property of the plasmin/plasminogen system: the use of plasmin (ogen) for cell detachment and disaggregation in cell culture technique
WO1989005342A1 (en) Process for the production of human factor viii by culturing a human hepatoma cell line
Seegers et al. Isolation of thrombin-E and the evolution of enzyme activity from prothrombin
Banaś-Gruszka et al. Amino acid composition ana N-terminal residues of goose, duck and hen prothrombin
EA041947B1 (ru) Способ получения рекомбинантного высокомолекулярного vwf в культуре клеток
HK1229339B (en) Method of producing recombinant high molecular weight vwf in cell culture

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: PHARMACIA AB

Free format text: FORMER NAME WAS: PHARMACIA AND UPJOHN AB

PC Assignment registered

Owner name: BIOVITRUM AB

Free format text: FORMER OWNER WAS: PHARMACIA AB